M
MRM Health NV
Microbiome-based therapeutics using a proprietary platform to design, optimise, and manufacture live bacterial consortia as drugs
About MRM Health NV
MRM Health NV is a clinical-stage biopharmaceutical company, established in 2020 and headquartered in Ghent, Belgium. The company was founded by CEO Dr. Sam Possemiers, who brings over 15 years of expertise in gut microbiology and host-microbiome interactions from both academic and industrial settings. His entrepreneurial background includes co-founding ProDigest and MRM Technologies, the latter of which, a center for microbiome R&D, established MRM Health as a joint venture with the life sciences research institute VIB.
The company focuses on developing live biotherapeutic products by targeting the human microbiome to address a range of inflammatory, central nervous system, and metabolic diseases. MRM Health's business model revolves around the discovery, development, and potential commercialization of these novel therapeutics. This is achieved through a combination of in-house programs and strategic collaborations, such as its partnership with IFF (formerly DuPont Nutrition & Biosciences) to co-develop treatments for metabolic diseases like Type 2 Diabetes. The company is backed by a consortium of local and international investors, including Ackermans & van Haaren, IFF, Qbic II, and VIB.
At the core of its operations is the proprietary CORAL® platform, a technology designed to overcome key challenges in microbiome therapeutic development. This platform integrates a bioinformatics-guided discovery engine with a unique optimization and manufacturing process. It allows for the rational selection of 5 to 10 bacterial strains that work synergistically and can be produced as a single drug substance, streamlining development and enhancing scalability. A key feature is the use of tools like the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) to test consortia before clinical trials.
MRM Health's lead product candidate, MH002, is an optimized consortium of six commensal strains aimed at treating Inflammatory Bowel Diseases. The company has reported positive topline results from a Phase 2a clinical study in mild-to-moderate Ulcerative Colitis and is also evaluating MH002 in patients with Pouchitis, an orphan disease. Beyond its lead program, the pipeline includes preclinical candidates for Parkinson's Disease and autoimmune disorders.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $61M | $242M | Flanders Institute for Biotechnology · BIOCODEX · Athos · Qbic Fund | ↗ |
| GRANTOther financing | Mar 2023 | $2.2M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for MRM Health NV is 10 monthly website visits, down 99.3% over the last three months. MRM Health NV's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
MRM Health NV in the Ghent ecosystem
The MRM Health NV office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Qbic Fund
Ackermans & van Haaren
DuPont
Flanders Institute for Biotechnology
BIOCODEX- ATAthos
SFPIM
BNP Paribas Fortis
OMX Ventures
Other known investors2 additional known investors
Ghent University
KU Leuven
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MRM Health NV on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MRM Health NV’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










